Go Pro
→ Bezos… DOOMED (From Paradigm Press) (Ad)tc pixel Free CRNX Stock Alerts

Crinetics Pharmaceuticals (CRNX) Financials

Crinetics Pharmaceuticals logo
$84.95 0.00 (0.00%)
As of 09/1/2026
Compare
Annual Income Statements for Crinetics Pharmaceuticals

Annual Income Statements for Crinetics Pharmaceuticals

This table shows Crinetics Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -6.02 -9.16 -27 -50 -74 -108 -164 -215 -298 -465
Consolidated Net Income / (Loss)		 -6.02 -9.16 -27 -50 -74 -108 -164 -215 -298 -465
Net Income / (Loss) Continuing Operations		 -6.02 -9.16 -27 -50 -74 -108 -164 -215 -298 -465
Total Pre-Tax Income 		-6.02 -9.16 -27 -50 -74 -108 -164 -209 -298 -465
Total Operating Income		 -6.04 -9.13 -29 -54 -75 -108 -168 -223 -339 -517
Total Gross Profit		 0.59 2.05 2.43 1.19 0.14 1.08 4.74 4.01 1.04 6.62
Total Revenue		 0.59 2.05 2.43 1.19 0.14 1.08 4.74 4.01 1.04 7.70
Operating Revenue		 0.59 2.05 2.43 1.19 0.14 1.08 4.74 4.01 1.04 7.70
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.08
Operating Cost of Revenue		 - - - - - - - 0.00 0.00 1.08
Total Operating Expenses		 6.63 11 31 55 75 109 173 227 340 523
Selling, General & Admin Expense		 1.53 1.94 6.66 14 18 25 42 58 100 191
Research & Development Expense		 5.10 9.23 24 42 57 84 130 169 240 332
Total Other Income / (Expense), net		 0.03 -0.03 1.60 3.41 0.99 0.16 3.96 13 41 52
Interest & Investment Income		 0.04 0.03 1.75 3.46 0.99 0.16 3.31 13 41 52
Other Income / (Expense), net		 -0.00 -0.05 -0.15 -0.05 0.00 0.00 0.66 -0.16 -0.52 -0.36
Income Tax Expense		 - - - - - - - 0.00 0.00 0.18
Other Gains / (Losses), net		 - - - - - - - -5.20 -0.47 0.00
Basic Earnings per Share		 ($5.96) ($6.68) ($2.23) ($2.09) ($2.42) ($2.80) ($3.15) ($3.69) ($3.69) ($4.95)
Weighted Average Basic Shares Outstanding		 1.01M 1.37M 12.14M 24.18M 30.45M 38.44M 51.98M 58.07M 80.78M 94.06M
Diluted Earnings per Share		 ($5.96) ($6.68) ($2.23) ($2.09) ($2.42) ($2.80) ($3.15) ($3.69) ($3.69) ($4.95)
Weighted Average Diluted Shares Outstanding		 1.01M 1.37M 12.14M 24.18M 30.45M 38.44M 51.98M 58.07M 80.78M 94.06M
Weighted Average Basic & Diluted Shares Outstanding		 1.01M 1.37M 12.14M 24.18M 30.45M 38.44M 53.91M 69.60M 93.05M 104.71M

Quarterly Income Statements for Crinetics Pharmaceuticals

This table shows Crinetics Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -61 -67 -74 -77 -83 -97 -116 -130 -123 -128 -121
Consolidated Net Income / (Loss)		 -60 -67 -74 -77 -81 -97 -116 -130 -123 -128 -121
Net Income / (Loss) Continuing Operations		 -60 -67 -74 -77 -81 -97 -116 -130 -123 -128 -121
Total Pre-Tax Income 		-60 -67 -74 -77 -81 -97 -116 -130 -123 -128 -121
Total Operating Income		 -63 -74 -83 -88 -95 -111 -129 -143 -134 -140 -132
Total Gross Profit		 - 0.64 0.40 0.00 - 0.72 1.03 0.14 5.09 11 25
Total Revenue		 - 0.64 0.40 0.00 - 0.72 1.03 0.14 6.16 11 25
Operating Revenue		 - 0.64 0.40 0.00 - 0.72 1.03 0.14 6.16 11 25
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 1.08 0.20 0.15
Operating Cost of Revenue		 - - - - - 0.00 0.00 - - 0.20 0.15
Total Operating Expenses		 63 74 83 88 95 112 130 143 139 151 157
Selling, General & Admin Expense		 17 21 25 26 28 36 50 52 54 51 58
Research & Development Expense		 46 53 58 62 67 76 80 90 85 100 100
Total Other Income / (Expense), net		 2.56 6.60 8.73 11 14 15 13 12 11 13 12
Interest & Investment Income		 2.52 6.85 8.74 11 14 15 13 13 11 13 12
Other Income / (Expense), net		 - -0.25 -0.01 -0.04 - -0.20 0.02 -0.05 -0.13 -0.13 -0.42
Basic Earnings per Share		 ($0.89) ($0.93) ($0.94) ($0.96) ($0.86) ($1.04) ($1.23) ($1.38) ($1.30) ($1.23) ($1.14)
Weighted Average Basic Shares Outstanding		 58.07M 72.29M 79.01M 80.09M 80.78M 93.10M 93.79M 94.22M 94.06M 104.10M 105.56M
Diluted Earnings per Share		 ($0.89) ($0.93) ($0.94) ($0.96) ($0.86) ($1.04) ($1.23) ($1.38) ($1.30) ($1.23) ($1.14)
Weighted Average Diluted Shares Outstanding		 58.07M 72.29M 79.01M 80.09M 80.78M 93.10M 93.79M 94.22M 94.06M 104.10M 105.56M
Weighted Average Basic & Diluted Shares Outstanding		 69.60M 78.86M 80.04M 92.74M 93.05M 93.68M 94.18M 94.89M 104.71M 105.44M 106.07M

Annual Cash Flow Statements for Crinetics Pharmaceuticals

This table details how cash moves in and out of Crinetics Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -5.71 2.04 31 -4.65 53 108 -167 22 210 -163
Net Cash From Operating Activities		 -5.47 -9.48 -19 -46 -62 -89 -115 -169 -230 -378
Net Cash From Continuing Operating Activities		 -5.47 -9.48 -19 -46 -62 -89 -115 -169 -230 -378
Net Income / (Loss) Continuing Operations		 -6.02 -9.16 -27 -50 -74 -108 -164 -215 -298 -465
Consolidated Net Income / (Loss)		 -6.02 -9.16 -27 -50 -74 -108 -164 -215 -298 -465
Depreciation Expense		 0.09 0.13 0.47 0.89 0.95 0.92 0.98 1.10 2.79 3.89
Amortization Expense		 - - -0.43 -1.23 -0.23 0.42 0.03 -8.27 -15 -15
Non-Cash Adjustments To Reconcile Net Income		 0.27 0.27 2.32 6.52 11 17 29 47 73 94
Changes in Operating Assets and Liabilities, net		 0.19 -0.72 5.30 -2.13 0.38 1.10 19 5.75 7.41 4.84
Net Cash From Investing Activities		 -0.19 -0.30 -119 42 0.22 -56 -174 -200 -575 174
Net Cash From Continuing Investing Activities		 -0.19 -0.30 -119 42 0.22 -56 -174 -200 -575 174
Purchase of Property, Plant & Equipment		 -0.19 -0.30 -1.06 -0.49 -0.19 -0.44 -1.66 -4.69 -3.84 -5.76
Purchase of Investments		 - - -118 -108 -136 -125 -330 -528 -1,147 -1,004
Sale and/or Maturity of Investments		 - - 0.00 150 136 69 157 337 576 1,184
Other Investing Activities, net		 - - - - - - 0.00 -5.00 0.00 0.00
Net Cash From Financing Activities		 -0.05 12 170 0.07 115 253 122 391 1,015 41
Net Cash From Continuing Financing Activities		 -0.05 12 170 0.07 115 253 122 391 1,015 41
Repurchase of Common Equity		 - - - - - - - -0.54 -15 0.00
Issuance of Common Equity		 - - 106 0.00 114 250 117 370 985 0.00
Other Financing Activities, net		 - 0.07 0.45 0.13 0.29 3.14 4.72 22 45 41

Quarterly Cash Flow Statements for Crinetics Pharmaceuticals

This table details how cash moves in and out of Crinetics Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -88 341 -94 15 -53 -170 -41 57 -9.76 13 -59
Net Cash From Operating Activities		 -39 -53 -46 -63 -65 -88 -86 -111 -93 -125 -94
Net Cash From Continuing Operating Activities		 -39 -53 -46 -63 -65 -88 -86 -111 -93 -125 -93
Net Income / (Loss) Continuing Operations		 -60 -67 -74 -77 -81 -97 -116 -130 -123 -128 -121
Consolidated Net Income / (Loss)		 -60 -67 -74 -77 -81 -97 -116 -130 -123 -128 -121
Depreciation Expense		 0.26 0.47 0.75 0.77 0.79 0.93 0.96 1.01 0.99 1.16 1.07
Amortization Expense		 -3.58 -3.85 -3.41 -3.51 -4.16 -3.56 -4.71 -3.60 -2.73 -2.22 -0.64
Non-Cash Adjustments To Reconcile Net Income		 17 15 20 19 20 20 27 21 25 29 26
Changes in Operating Assets and Liabilities, net		 8.30 2.69 11 -2.15 -0.31 -9.54 6.60 1.08 6.69 -26 1.36
Net Cash From Investing Activities		 -87 0.31 -54 21 -542 -86 38 165 57 -252 26
Net Cash From Continuing Investing Activities		 -87 0.31 -54 21 -542 -86 38 165 57 -253 27
Purchase of Property, Plant & Equipment		 -0.94 -1.33 -0.96 -0.53 -1.03 -1.24 -3.20 -0.86 -0.46 -1.28 -0.06
Purchase of Investments		 -168 -100 -192 -130 -725 -391 -183 -217 -214 -554 -155
Sale and/or Maturity of Investments		 87 101 139 151 184 306 224 382 271 303 182
Net Cash From Financing Activities		 38 394 5.50 57 554 4.44 7.06 3.08 26 390 8.93
Net Cash From Continuing Financing Activities		 38 394 5.50 57 554 4.44 7.06 3.08 26 390 8.93
Other Financing Activities, net		 9.17 10 9.81 11 9.54 4.44 7.06 3.08 26 9.94 8.93

Annual Balance Sheets for Crinetics Pharmaceuticals

This table presents Crinetics Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 16 130 183 351 352 635 1,435 1,126
Total Current Assets		 15 123 177 345 345 574 1,375 1,048
Cash & Equivalents		 14 40 93 201 33 55 265 102
Short-Term Investments		 - 78 78 133 302 504 1,090 926
Accounts Receivable		 - - - - - - 0.00 0.59
Inventories, net		 - - - - - - 0.00 2.02
Prepaid Expenses		 0.97 4.95 6.61 11 11 16 21 18
Plant, Property, & Equipment, net		 0.40 3.95 3.18 2.83 3.50 11 12 14
Total Noncurrent Assets		 0.03 3.09 2.77 3.47 3.49 50 47 64
Other Noncurrent Operating Assets		 0.03 3.09 2.77 2.46 3.49 50 47 64
Total Liabilities & Shareholders' Equity		 16 130 183 351 352 635 1,435 1,126
Total Liabilities		 0.92 13 15 19 36 96 110 134
Total Current Liabilities		 0.90 8.34 10 16 28 44 60 85
Accounts Payable		 0.40 5.50 5.59 8.47 15 23 21 42
Accrued Expenses		 0.18 2.12 4.07 6.59 9.08 15 29 36
Current Deferred Revenue		 - - - 0.00 2.24 2.06 2.18 1.24
Other Current Liabilities		 - 0.72 0.84 0.94 1.05 4.17 7.15 6.49
Total Noncurrent Liabilities		 0.02 4.90 4.04 3.08 8.13 52 50 49
Noncurrent Deferred Revenue		 0.02 - - 0.00 6.10 4.75 4.70 3.81
Other Noncurrent Operating Liabilities		 - 4.85 4.01 3.07 2.02 48 45 45
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -15 117 169 332 316 539 1,325 992
Total Preferred & Common Equity		 -15 117 169 332 316 539 1,325 992
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -15 117 169 332 316 539 1,325 992
Common Stock		 1.24 211 337 608 759 1,192 2,276 2,408
Retained Earnings		 -16 -94 -168 -275 -439 -654 -952 -1,417
Accumulated Other Comprehensive Income / (Loss)		 - 0.15 0.03 -0.38 -3.93 0.98 0.96 1.87
Other Equity Adjustments		 - - - - - - 0.00 -0.11

Quarterly Balance Sheets for Crinetics Pharmaceuticals

This table presents Crinetics Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 314 293 642 978 936 937 1,361 1,290 1,196 1,401 1,322
Total Current Assets		 305 285 576 917 875 878 1,291 1,217 1,121 1,322 1,244
Cash & Equivalents		 41 40 143 396 302 317 95 54 111 114 55
Short-Term Investments		 255 225 412 505 561 545 1,180 1,143 981 1,177 1,150
Accounts Receivable		 - - - - - - - - - 5.68 12
Inventories, net		 - - - - - - - - - 3.06 3.49
Prepaid Expenses		 9.28 20 21 16 12 15 16 20 28 22 23
Plant, Property, & Equipment, net		 3.27 3.22 9.76 12 12 12 13 15 14 13 13
Total Noncurrent Assets		 5.34 5.22 56 49 49 48 58 58 60 65 64
Other Noncurrent Operating Assets		 5.34 5.22 51 49 49 48 58 58 60 65 64
Total Liabilities & Shareholders' Equity		 314 293 642 978 936 937 1,361 1,290 1,196 1,401 1,322
Total Liabilities		 34 39 94 103 105 104 107 118 124 121 130
Total Current Liabilities		 26 33 40 52 54 54 57 68 74 71 80
Accounts Payable		 16 21 22 29 24 18 32 38 34 37 42
Accrued Expenses		 6.83 8.60 13 15 20 26 17 22 32 26 29
Current Deferred Revenue		 2.12 2.08 1.66 2.46 2.56 1.69 2.21 1.90 1.64 1.27 1.67
Other Current Liabilities		 1.08 1.11 3.99 5.79 7.45 7.41 6.88 6.61 6.44 6.54 6.59
Total Noncurrent Liabilities		 7.36 6.53 53 51 50 51 50 50 50 50 50
Noncurrent Deferred Revenue		 5.62 5.07 5.14 4.74 4.32 5.20 4.31 3.99 4.11 3.35 3.47
Other Noncurrent Operating Liabilities		 1.74 1.46 48 47 46 46 46 46 46 46 47
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 280 254 548 875 831 833 1,254 1,172 1,072 1,281 1,192
Total Preferred & Common Equity		 280 254 548 875 831 833 1,254 1,172 1,072 1,281 1,192
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 280 254 548 875 831 833 1,254 1,172 1,072 1,281 1,192
Common Stock		 768 792 1,142 1,595 1,626 1,702 2,301 2,335 2,365 2,828 2,862
Retained Earnings		 -485 -536 -594 -721 -795 -872 -1,049 -1,165 -1,295 -1,545 -1,666
Accumulated Other Comprehensive Income / (Loss)		 -2.51 -1.71 -0.87 0.15 -0.19 2.04 2.00 1.62 2.19 -1.25 -3.01
Other Equity Adjustments		 - - - - - - - -0.11 -0.11 -1.03 -1.26

Annual Metrics And Ratios for Crinetics Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Crinetics Pharmaceuticals' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 247.20% 18.73% -50.86% -88.10% 659.15% 339.42% -15.28% -74.11% 640.71%
EBITDA Growth		 0.00% -51.97% -218.61% -88.11% -36.90% -43.28% -56.27% -37.14% -54.22% -50.39%
EBIT Growth		 0.00% -51.78% -214.58% -86.68% -39.11% -43.69% -55.27% -33.21% -52.34% -52.38%
NOPAT Growth		 0.00% -51.01% -214.56% -87.50% -39.24% -43.69% -55.88% -32.60% -52.22% -52.50%
Net Income Growth		 0.00% -52.13% -196.11% -85.96% -46.39% -45.83% -52.28% -30.88% -39.10% -55.93%
EPS Growth		 0.00% -12.08% 66.62% 6.28% -15.79% -15.70% -12.50% -17.14% 0.00% -34.15%
Operating Cash Flow Growth		 0.00% -73.35% -105.29% -138.35% -33.73% -42.82% -30.05% -44.36% -35.88% -64.18%
Free Cash Flow Firm Growth		 0.00% 0.00% -185.26% -85.76% -42.08% -44.09% -37.03% -50.70% -47.63% -56.45%
Invested Capital Growth		 0.00% 0.00% -100.00% 0.00% -56.50% -41.41% -552.61% -10.07% -49.43% -20.30%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 1,418.31% -23.40% -15.01% 0.00% 401.37%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -6,361.43% -17,009.34% -9.21% -11.02% -8.84% -10.24% -7.57%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -9.23% -10.59% -7.35% -10.63% -8.12%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -9.23% -11.02% -7.28% -10.46% -8.15%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -9.29% -9.48% -7.57% -7.38% -9.98%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -2.19% -5.00% -1.65% 0.81% -9.76%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -21.92% -19.10% -4.18% -8.53% -11.96% -2.03% -13.09% -8.70%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -1,931.36% -8.26% -15.35% -2.21% -15.63% -3.53%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 41.72% -592.71% -1,146.42% -6.52% -72.07% -0.26% -73.63%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 86.02%
EBITDA Margin		 -1,010.70% -442.40% -1,187.19% -4,545.18% -52,276.06% -9,866.23% -3,508.72% -5,680.04% -33,832.44% -6,869.30%
Operating Margin		 -1,026.15% -446.31% -1,182.45% -4,512.32% -52,783.80% -9,990.91% -3,544.06% -5,547.17% -32,613.47% -6,714.77%
EBIT Margin		 -1,026.32% -448.66% -1,188.76% -4,516.51% -52,783.80% -9,990.91% -3,530.19% -5,551.13% -32,663.43% -6,719.41%
Profit (Net Income) Margin		 -1,021.90% -447.78% -1,116.76% -4,226.49% -51,980.28% -9,985.25% -3,460.38% -5,345.85% -28,720.69% -6,046.22%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 99.80% 100.09% 100.00% 100.00% 100.00% 100.04%
Interest Burden Percent		 99.57% 99.80% 93.94% 93.58% 98.68% 99.85% 98.02% 96.30% 87.93% 89.95%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -2,629.18% -8,270.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -2,590.17% -8,171.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 2,504.41% 7,900.91% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -124.77% -369.46% -86.09% -51.61% -42.98% -50.57% -50.16% -32.02% -40.17%
Cash Return on Invested Capital (CROIC)		 0.00% -2,829.18% -8,070.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -58.82% -370.09% -82.66% -47.77% -40.30% -47.56% -45.12% -32.79% -40.39%
Return on Assets (ROA)		 0.00% -58.71% -347.67% -77.35% -47.04% -40.28% -46.62% -43.45% -28.83% -36.34%
Return on Common Equity (ROCE)		 0.00% 127.70% 378.12% -86.09% -51.61% -42.98% -50.57% -50.16% -32.02% -40.17%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 60.96% 0.00% -43.04% -43.70% -32.43% -51.82% -39.79% -22.52% 0.00%
Net Operating Profit after Tax (NOPAT)		 -4.23 -6.39 -20 -38 -52 -75 -118 -156 -237 -362
NOPAT Margin		 -718.30% -312.42% -827.72% -3,158.63% -36,948.66% -6,993.64% -2,480.84% -3,883.02% -22,829.43% -4,700.34%
Net Nonoperating Expense Percent (NNEP)		 0.00% -39.01% -98.90% -21.52% -14.76% -12.76% -13.87% -13.14% -6.40% -8.70%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -37.15% -28.90% -17.90% -36.46%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 13.98%
SG&A Expenses to Revenue		 260.27% 94.82% 274.26% 1,133.19% 12,694.37% 2,275.05% 894.95% 1,447.65% 9,599.33% 2,486.11%
R&D to Revenue		 865.87% 451.49% 1,008.20% 3,479.13% 40,139.44% 7,815.86% 2,749.10% 4,199.53% 23,114.15% 4,314.68%
Operating Expenses to Revenue		 1,126.15% 546.31% 1,282.45% 4,612.32% 52,728.17% 10,099.81% 3,644.06% 5,647.17% 32,713.47% 6,800.79%
Earnings before Interest and Taxes (EBIT)		 -6.05 -9.18 -29 -54 -75 -108 -167 -223 -339 -517
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.95 -9.05 -29 -54 -74 -106 -166 -228 -352 -529
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 5.19 2.75 4.07 3.11 3.56 2.08 2.53
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 5.19 2.75 4.07 3.11 3.56 2.08 2.53
Price to Revenue (P/Rev)		 173.17 49.88 296.90 509.42 3,271.37 1,251.83 207.88 477.97 2,652.90 326.07
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 241.79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 57.46 296.90 410.18 2,067.99 941.33 137.28 338.66 1,349.17 192.51
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -0.97 -0.97 -1.01 -1.01 -1.01 -1.03 -1.04 -1.03 -1.03
Leverage Ratio		 0.00 1.06 1.06 1.11 1.10 1.07 1.08 1.15 1.11 1.11
Compound Leverage Factor		 0.00 1.06 1.00 1.04 1.08 1.07 1.06 1.11 0.98 0.99
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 202.34% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -102.34% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 64.35 0.00 26.24 17.65 41.47 14.26 10.37 14.46 8.98
Noncontrolling Interest Sharing Ratio		 0.00% 202.34% 202.34% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 16.91 0.00 14.79 16.92 21.55 12.45 13.07 23.04 12.32
Quick Ratio		 0.00 15.82 0.00 14.20 16.29 20.86 12.06 12.71 22.69 12.09
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -6.87 -20 -36 -52 -75 -102 -154 -227 -356
Operating Cash Flow to CapEx		 -2,877.89% -3,118.09% -1,837.49% -9,427.03% -33,347.85% -20,318.35% -6,956.82% -3,547.50% -5,878.51% -6,558.87%
Free Cash Flow to Firm to Interest Expense		 0.00 -859.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -497.09 -1,184.88 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -514.36 -1,222.88 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.13 0.31 0.02 0.00 0.00 0.01 0.01 0.00 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 5.11 0.00 0.00 0.04 0.36 1.50 0.56 0.09 0.58
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10,725.95
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -10,725.95
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 0.49 0.00 -1.25 -1.96 -2.77 -18 -20 -30 -36
Invested Capital Turnover		 0.00 8.42 9.99 -1.90 -0.09 -0.46 -0.45 -0.21 -0.04 -0.23
Increase / (Decrease) in Invested Capital		 0.00 0.49 -0.49 -1.25 -0.71 -0.81 -15 -1.82 -9.85 -6.04
Enterprise Value (EV)		 0.00 118 721 489 294 1,015 650 1,359 1,402 1,482
Market Capitalization		 102 102 721 608 465 1,349 985 1,918 2,756 2,509
Book Value per Share		 $0.00 ($10.96) $0.00 $4.84 $5.13 $6.99 $5.88 $8.07 $14.29 $10.45
Tangible Book Value per Share		 $0.00 ($10.96) $0.00 $4.84 $5.13 $6.99 $5.88 $8.07 $14.29 $10.45
Total Capital		 0.00 15 0.00 117 169 332 316 539 1,325 992
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -14 0.00 -118 -171 -335 -334 -559 -1,355 -1,028
Capital Expenditures (CapEx)		 0.19 0.30 1.06 0.49 0.19 0.44 1.66 4.69 3.84 5.76
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.08 0.00 -3.39 -3.88 -4.98 -17 -28 -39 -65
Debt-free Net Working Capital (DFNWC)		 0.00 14 0.00 115 167 329 317 530 1,316 963
Net Working Capital (NWC)		 0.00 14 0.00 115 167 329 317 530 1,316 963
Net Nonoperating Expense (NNE)		 1.79 2.77 7.02 13 21 32 46 59 61 104
Net Nonoperating Obligations (NNO)		 0.00 -14 0.00 -118 -171 -335 -334 -559 -1,355 -1,028
Total Depreciation and Amortization (D&A)		 0.09 0.13 0.04 -0.34 0.72 1.34 1.02 -5.17 -12 -12
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 3.72% 0.00% -284.41% -2,730.28% -462.15% -358.12% -706.30% -3,740.62% -839.64%
Debt-free Net Working Capital to Revenue		 0.00% 697.70% 0.00% 9,639.48% 117,607.75% 30,493.97% 6,701.73% 13,212.33% 126,631.76% 12,516.50%
Net Working Capital to Revenue		 0.00% 697.70% 0.00% 9,639.48% 117,607.75% 30,493.97% 6,701.73% 13,212.33% 126,631.76% 12,516.50%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($5.96) ($6.68) ($2.23) $0.00 ($2.42) ($2.80) ($3.15) ($3.69) ($3.69) ($4.95)
Adjusted Weighted Average Basic Shares Outstanding		 1.01M 1.37M 24.10M 0.00 33.03M 47.78B 51.98M 58.07M 80.78M 94.06M
Adjusted Diluted Earnings per Share		 ($5.96) ($6.68) ($2.23) $0.00 ($2.42) ($2.80) ($3.15) ($3.69) ($3.69) ($4.95)
Adjusted Weighted Average Diluted Shares Outstanding		 1.01M 1.37M 24.10M 0.00 33.03M 47.78B 51.98M 58.07M 80.78M 94.06M
Adjusted Basic & Diluted Earnings per Share		 ($5.96) ($6.68) ($2.23) $0.00 ($2.42) ($2.80) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.01M 1.37M 12.14M 0.00 30.45M 38.44M 53.91M 69.60M 93.05M 104.71M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.23 -6.39 -20 -38 -52 -75 -118 -156 -237 -362
Normalized NOPAT Margin		 -718.30% -312.42% -827.72% -3,158.63% -36,948.66% -6,993.64% -2,480.84% -3,883.02% -22,829.43% -4,700.34%
Pre Tax Income Margin		 -1,021.90% -447.78% -1,116.76% -4,226.49% -52,085.92% -9,976.35% -3,460.38% -5,345.85% -28,720.69% -6,043.88%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -549.55 -1,146.88 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -384.62 -798.61 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -566.82 -1,184.88 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -401.89 -836.61 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Crinetics Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Crinetics Pharmaceuticals' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 104,705,330.00 105,440,208.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 104,705,330.00 105,440,208.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -1.22 -1.15
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% -76.11% -59.62% -100.00% 0.00% -43.59% 158.40% 0.00% 0.00% 1,386.70% 2,336.28%
EBITDA Growth		 -38.53% -59.47% -59.08% -50.95% -48.71% -49.13% -55.47% -60.33% -37.82% -23.92% 0.91%
EBIT Growth		 -31.76% -53.26% -55.97% -48.80% -51.21% -51.27% -55.92% -62.39% -40.89% -25.90% -2.94%
NOPAT Growth		 -31.76% -53.26% -56.21% -48.87% -51.21% -51.51% -55.96% -62.40% -41.08% -26.01% -2.59%
Net Income Growth		 -33.58% -45.52% -45.27% -33.71% -34.11% -44.59% -56.15% -69.33% -52.39% -32.11% -4.51%
EPS Growth		 -7.23% -9.41% 0.00% 4.95% 3.37% -11.83% -30.85% -43.75% -51.16% -18.27% 7.32%
Operating Cash Flow Growth		 -9.40% -29.81% 0.26% -51.97% -67.92% -67.35% -80.19% -76.24% -38.93% -40.98% -9.72%
Free Cash Flow Firm Growth		 -134.00% -19.38% 26.22% 7.18% -34.34% -102.23% -168.82% -151.18% -54.97% -29.79% -7.21%
Invested Capital Growth		 -10.07% -64.82% -209.13% -156.46% -49.43% 20.76% 21.30% 30.54% -20.30% 48.31% 45.48%
Revenue Q/Q Growth		 0.00% 0.00% -37.66% -100.00% 0.00% 0.00% 185.60% -86.13% 4,208.39% 74.23% 134.00%
EBITDA Q/Q Growth		 -9.96% -16.55% -11.12% -6.00% -8.33% -17.26% -15.46% -9.32% 6.67% -4.46% 6.44%
EBIT Q/Q Growth		 -6.15% -17.35% -12.60% -6.08% -7.87% -17.80% -15.67% -10.49% 6.20% -5.02% 5.43%
NOPAT Q/Q Growth		 -6.24% -17.35% -12.59% -6.06% -7.91% -17.58% -15.89% -10.44% 6.26% -5.02% 5.64%
Net Income Q/Q Growth		 -4.59% -11.37% -10.65% -3.74% -4.90% -20.07% -19.49% -12.50% 5.59% -4.10% 5.47%
EPS Q/Q Growth		 11.88% -4.49% -1.08% -2.13% 10.42% -20.93% -18.27% -12.20% 5.80% 5.38% 7.32%
Operating Cash Flow Q/Q Growth		 6.83% -37.23% 13.70% -37.72% -2.95% -36.77% 2.94% -28.97% 16.09% -34.23% 24.47%
Free Cash Flow Firm Q/Q Growth		 9.98% 1.91% 12.28% -19.84% -30.29% -47.65% -16.61% -11.97% 19.61% -23.66% 3.68%
Invested Capital Q/Q Growth		 -72.07% -30.67% -23.67% 7.77% -0.26% 30.71% -22.84% 18.60% -73.63% 70.23% -29.56%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 0.00% 0.00% 100.00% 100.00% 100.00% 82.54% 98.14% 99.39%
EBITDA Margin		 0.00% -12,015.94% -21,416.29% 0.00% 0.00% -31,872.30% -12,885.26% -101,555.24% -2,199.82% -1,318.88% -527.30%
Operating Margin		 0.00% -11,488.91% -20,747.62% 0.00% 0.00% -30,860.11% -12,522.99% -99,710.49% -2,169.55% -1,307.79% -527.35%
EBIT Margin		 0.00% -11,488.91% -20,750.88% 0.00% 0.00% -30,916.34% -12,521.05% -99,744.76% -2,171.58% -1,309.01% -529.03%
Profit (Net Income) Margin		 0.00% -10,457.81% -18,560.15% 0.00% 0.00% -26,807.20% -11,216.00% -90,972.73% -1,993.43% -1,191.03% -481.15%
Tax Burden Percent		 99.91% 100.38% 100.00% 100.00% 99.69% 100.00% 100.00% 100.00% 100.15% 100.00% 100.00%
Interest Burden Percent		 96.00% 90.68% 89.44% 87.47% 85.33% 86.71% 89.58% 91.21% 91.66% 90.99% 90.95%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -50.16% -40.76% -47.66% -40.26% -32.02% -30.84% -36.94% -44.42% -40.17% -39.17% -42.45%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -35.10% -46.78% 0.00% 0.00% -20.09% -15.67% -143.53% -13.05% -16.78% -16.93%
Return on Assets (ROA)		 0.00% -31.95% -41.84% 0.00% 0.00% -17.42% -14.03% -130.91% -11.98% -15.27% -15.40%
Return on Common Equity (ROCE)		 -50.16% -40.76% -47.66% -40.26% -32.02% -30.84% -36.94% -44.42% -40.17% -39.17% -42.45%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -26.91% -31.12% -33.36% 0.00% -26.18% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -44 -51 -58 -61 -66 -78 -90 -100 -94 -98 -93
NOPAT Margin		 0.00% -8,042.23% -14,523.33% 0.00% 0.00% -21,602.08% -8,766.09% -69,797.34% -1,518.69% -915.45% -369.14%
Net Nonoperating Expense Percent (NNEP)		 -3.63% -2.58% -2.86% -2.16% -1.49% -1.73% -2.45% -3.10% -2.46% -2.31% -2.34%
Return On Investment Capital (ROIC_SIMPLE)		 -8.14% - - - -5.01% -6.22% -7.71% -9.31% -9.43% -7.67% -7.78%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 17.46% 1.86% 0.61%
SG&A Expenses to Revenue		 0.00% 3,254.38% 6,225.06% 0.00% 0.00% 9,841.00% 4,834.34% 36,548.95% 871.58% 473.55% 229.21%
R&D to Revenue		 0.00% 8,334.53% 14,622.56% 0.00% 0.00% 21,119.11% 7,788.65% 63,261.54% 1,380.51% 932.37% 397.52%
Operating Expenses to Revenue		 0.00% 11,588.91% 20,847.62% 0.00% 0.00% 30,960.11% 12,622.99% 99,810.49% 2,252.09% 1,405.93% 626.73%
Earnings before Interest and Taxes (EBIT)		 -63 -74 -83 -88 -95 -112 -129 -143 -134 -141 -133
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -66 -77 -85 -91 -98 -115 -133 -145 -136 -142 -132
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.56 2.88 2.91 3.31 2.08 1.44 1.32 2.09 2.53 1.53 1.69
Price to Tangible Book Value (P/TBV)		 3.56 2.88 2.91 3.31 2.08 1.44 1.32 2.09 2.53 1.53 1.69
Price to Revenue (P/Rev)		 477.97 1,278.36 1,743.38 2,651.34 2,652.90 2,379.08 1,113.81 1,462.74 326.07 110.57 48.27
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 338.66 821.94 1,120.31 1,821.05 1,349.17 701.95 253.99 750.82 192.51 37.65 19.42
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.04 -1.04 -1.04 -1.03 -1.03 -1.02 -1.03 -1.03 -1.03 -1.01 -1.02
Leverage Ratio		 1.15 1.12 1.13 1.14 1.11 1.10 1.11 1.12 1.11 1.09 1.10
Compound Leverage Factor		 1.11 1.01 1.01 1.00 0.95 0.95 1.00 1.02 1.01 0.99 1.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 11.20 14.45 13.40 15.28 15.02 9.85 7.36 10.02 10.10 8.94 8.31
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 13.07 17.72 16.09 16.38 23.04 22.53 17.80 15.12 12.32 18.60 15.57
Quick Ratio		 12.71 17.40 15.87 16.11 22.69 22.23 17.49 14.73 12.09 18.25 15.24
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -42 -41 -36 -43 -56 -83 -97 -109 -88 -108 -104
Operating Cash Flow to CapEx		 -4,119.25% -3,968.17% -4,776.65% -11,898.30% -6,285.13% -7,138.98% -2,681.17% -12,829.43% -20,284.06% -9,712.07% -165,250.88%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.03
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.56 0.26 0.18 0.10 0.09 0.06 0.10 0.12 0.58 1.36 3.01
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.04 0.04
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10,725.95 9,883.46 10,276.79
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -10,725.95 -9,883.46 -10,276.79
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -20 -26 -32 -30 -30 -21 -25 -21 -36 -11 -14
Invested Capital Turnover		 -0.21 -0.09 -0.07 -0.05 -0.04 -0.03 -0.05 -0.06 -0.23 -1.13 -2.14
Increase / (Decrease) in Invested Capital		 -1.82 -10 -22 -18 -9.85 5.40 6.86 9.07 -6.04 9.96 12
Enterprise Value (EV)		 1,359 1,623 1,552 1,892 1,402 533 354 1,153 1,482 667 811
Market Capitalization		 1,918 2,523 2,415 2,755 2,756 1,808 1,550 2,245 2,509 1,958 2,017
Book Value per Share		 $8.07 $12.57 $10.53 $10.41 $14.29 $13.48 $12.51 $11.38 $10.45 $12.23 $11.30
Tangible Book Value per Share		 $8.07 $12.57 $10.53 $10.41 $14.29 $13.48 $12.51 $11.38 $10.45 $12.23 $11.30
Total Capital		 539 875 831 833 1,325 1,254 1,172 1,072 992 1,281 1,192
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -559 -901 -863 -863 -1,355 -1,275 -1,197 -1,093 -1,028 -1,291 -1,206
Capital Expenditures (CapEx)		 0.94 1.33 0.96 0.53 1.03 1.24 3.20 0.86 0.46 1.28 0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -28 -36 -43 -39 -39 -41 -48 -46 -65 -40 -41
Debt-free Net Working Capital (DFNWC)		 530 865 820 824 1,316 1,234 1,149 1,047 963 1,251 1,164
Net Working Capital (NWC)		 530 865 820 824 1,316 1,234 1,149 1,047 963 1,251 1,164
Net Nonoperating Expense (NNE)		 16 15 16 15 14 19 25 30 29 30 28
Net Nonoperating Obligations (NNO)		 -559 -901 -863 -863 -1,355 -1,275 -1,197 -1,093 -1,028 -1,291 -1,206
Total Depreciation and Amortization (D&A)		 -3.32 -3.37 -2.66 -2.74 -3.38 -3.45 -3.76 -2.59 -1.74 -1.06 0.44
Debt-free, Cash-free Net Working Capital to Revenue		 -706.30% -1,798.38% -3,072.49% -3,719.25% -3,740.62% -5,378.95% -3,447.70% -2,975.31% -839.64% -225.76% -98.88%
Debt-free Net Working Capital to Revenue		 13,212.33% 43,843.01% 59,234.58% 79,309.43% 126,631.76% 162,334.74% 82,533.62% 68,216.29% 12,516.50% 7,066.46% 2,786.09%
Net Working Capital to Revenue		 13,212.33% 43,843.01% 59,234.58% 79,309.43% 126,631.76% 162,334.74% 82,533.62% 68,216.29% 12,516.50% 7,066.46% 2,786.09%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.89) ($0.93) ($0.94) ($0.96) ($0.86) ($1.04) ($1.23) ($1.38) ($1.30) ($1.23) ($1.14)
Adjusted Weighted Average Basic Shares Outstanding		 58.07M 72.29M 79.01M 80.09M 80.78M 93.10M 93.79M 94.22M 94.06M 104.10M 105.56M
Adjusted Diluted Earnings per Share		 ($0.89) ($0.93) ($0.94) ($0.96) ($0.86) ($1.04) ($1.23) ($1.38) ($1.30) ($1.23) ($1.14)
Adjusted Weighted Average Diluted Shares Outstanding		 58.07M 72.29M 79.01M 80.09M 80.78M 93.10M 93.79M 94.22M 94.06M 104.10M 105.56M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 69.60M 78.86M 80.04M 92.74M 93.05M 93.68M 94.18M 94.89M 104.71M 105.44M 106.07M
Normalized Net Operating Profit after Tax (NOPAT)		 -44 -51 -58 -61 -66 -78 -90 -100 -94 -98 -93
Normalized NOPAT Margin		 0.00% -8,042.23% -14,523.33% 0.00% 0.00% -21,602.08% -8,766.09% -69,797.34% -1,518.69% -915.45% -369.14%
Pre Tax Income Margin		 0.00% -10,418.59% -18,560.15% 0.00% 0.00% -26,807.20% -11,216.00% -90,972.73% -1,990.50% -1,191.03% -481.15%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.12% -0.12%

Financials Breakdown Chart

Key Financial Trends

Crinetics Pharmaceuticals (NASDAQ: CRNX) is showing strong commercial momentum, but it remains a heavily cash-burning biotechnology company. Revenue increased to $25.1 million in Q2 2026 from $10.7 million in Q1 2026, $6.2 million in Q4 2025 and just $143,000 in Q3 2025. The company generated a gross profit of $25.0 million in the latest quarter, implying a gross margin of approximately 99%.

The balance sheet remains a significant source of financial strength. Crinetics held $55.5 million in cash and equivalents and $1.15 billion in short-term investments at June 30, 2026. Although cash declined from $114.3 million at the end of Q1, total cash and short-term investments were approximately $1.21 billion. Total liabilities were only $129.9 million, compared with $1.19 billion of equity, and the provided statements show no traditional debt balance.

Profitability has not yet arrived. Q2 operating expenses rose to $157.4 million, including $99.9 million of research and development spending and $57.6 million of selling, general and administrative costs. The company reported a net loss of $120.9 million, although that was an improvement from the $127.8 million loss in Q1. Operating cash flow remained negative at $94.2 million in Q2, following a $124.7 million outflow in Q1.

  • Revenue is accelerating sharply. Quarterly revenue has climbed from less than $1 million throughout much of 2023 and 2024 to $25.1 million in Q2 2026, indicating meaningful progress in commercialization.
  • Gross margins are exceptionally high. Q2 revenue of $25.1 million and cost of revenue of only $154,000 produced approximately 99.4% gross margins, leaving substantial room for future revenue growth to help absorb operating costs.
  • Liquidity is substantial. Cash and short-term investments totaled approximately $1.21 billion at June 30, 2026, providing a sizeable funding base for clinical development and commercialization.
  • Balance-sheet leverage is low. Total liabilities of $129.9 million were modest relative to total assets of $1.32 billion and shareholders’ equity of $1.19 billion. The company also reported no commitments and contingencies in the supplied balance sheets.
  • Quarterly operating cash burn improved sequentially. Operating cash outflow declined from $124.7 million in Q1 2026 to $94.2 million in Q2, while the net loss narrowed by approximately $7.0 million.
  • Investment income is helping offset operating losses. Interest and investment income was $12.0 million in Q2 2026, but this source of income depends on the company’s cash holdings and prevailing interest rates rather than product profitability.
  • Investment portfolio activity is driving cash-flow volatility. Crinetics purchased $155.2 million of investments and received $182.0 million from investment sales and maturities in Q2. These transactions affect reported investing cash flow but do not necessarily represent changes in the company’s underlying operating performance.
  • The company continues to report significant losses. Net losses have widened from approximately $45.0 million in Q4 2022 to $120.9 million in Q2 2026 as development, commercial and administrative spending has increased.
  • Research and development spending remains elevated. R&D expense was nearly $100 million in Q2 2026, compared with $38.5 million in Q1 2023. This spending may support future growth, but it also keeps Crinetics far from operating breakeven.
  • Shareholder dilution has been substantial. Weighted-average basic shares increased from 51.98 million in Q4 2022 to 105.56 million in Q2 2026. The company raised approximately $380.5 million through common-equity issuance in Q1 2026 and $544.5 million in Q4 2024, allowing it to fund operations but reducing each existing shareholder’s ownership percentage.

Overall, Crinetics has moved from a development-stage company with minimal revenue toward a business producing increasingly meaningful product sales. Its large investment portfolio and limited liabilities reduce near-term financing risk. However, investors should continue monitoring revenue growth, operating expense discipline, cash burn and dilution because the company remains dependent on future commercial expansion to convert its strong gross margins into sustainable profitability.

09/04/26 08:27 PM ETAI Generated. May Contain Errors.

Crinetics Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Crinetics Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Crinetics Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$465.32 million in 2025, rising from -$6.02 million in 2016. The previous period was -$298.41 million in 2024. Find out what analysts predict for Crinetics Pharmaceuticals in the coming months.

Crinetics Pharmaceuticals' total operating income in 2025 was -$516.77 million, based on the following breakdown:
  • Total Gross Profit: $6.62 million
  • Total Operating Expenses: $523.39 million

Over the last 9 years, Crinetics Pharmaceuticals' total revenue changed from $589 thousand in 2016 to $7.70 million in 2025, a change of 1,206.6%.

Crinetics Pharmaceuticals' total liabilities were at $134.17 million at the end of 2025, a 22.2% increase from 2024, and a 14,484.1% increase since 2017.

In the past 7 years, Crinetics Pharmaceuticals' cash and equivalents has ranged from $14.19 million in 2017 to $264.55 million in 2024, and is currently $101.54 million as of their latest financial filing in 2025.

Over the last 9 years, Crinetics Pharmaceuticals' book value per share changed from 0.00 in 2016 to 10.45 in 2025, a change of 1,045.5%.


Related Companies

Financial statements for NASDAQ:CRNX last updated on 8/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
They're not buying gold. They're buying this.
Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...
Behind the Markets | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Congress Just Opened the Floodgates
The House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...
Awesomely | Sponsoredtc pixel
Wall Street pays $32K for this type of stock market data. (But see this Labor Day deal now!)
The Bloomberg Terminal costs $32,000 a year and sits on the desks of more than 350,000 Wall Street traders. Mo...
Weiss Ratings | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...
Eagle Publishing | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel